Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clemastine fumarate for remyelination in multiple sclerosis with internuclear ophthalmoparesis
NL-OMON60160Phase 3Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of clemastine in multiple sclerosis (MS) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Relative change in Versional Dysconjugacy Index area under the curve. Started Aug 2022; status: completed.
02
Drugs
clemastine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON60160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60160.